Kaposi's sarcoma-associated herpesvirus infection of bone marrow dendritic cells from multiple myeloma patients

Science

Volumn 276, Issue 5320, 1997, Pages 1851-1854

  Rettig, M B ^a,b   Ma, H J ^a   Vescio, R A ^a,b   Pold M ^a   Schiller, G ^b   Belson, D ^a   Savage, A ^b   Nishikubo, C ^b   Wu, C ^a   Fraser, J ^b   Said, J W ^b   Berenson, J R ^a,b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 6;

ARTICLE; BONE MARROW; CONTROLLED STUDY; DENDRITIC CELL; HERPES VIRUS INFECTION; HUMAN; HUMAN CELL; IN SITU HYBRIDIZATION; KAPOSI SARCOMA; MALIGNANT TRANSFORMATION; MONOCLONAL IMMUNOGLOBULINEMIA; MULTIPLE MYELOMA; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; VIRUS CARCINOGENESIS;

BLOTTING, SOUTHERN; BONE MARROW; CELL TRANSFORMATION, NEOPLASTIC; DENDRITIC CELLS; DNA, VIRAL; HERPESVIRUS 8, HUMAN; HL-60 CELLS; HUMANS; IN SITU HYBRIDIZATION; INTERLEUKIN-6; MULTIPLE MYELOMA; PARAPROTEINEMIAS; POLYMERASE CHAIN REACTION; STROMAL CELLS;

EID: 0030816233     PISSN: 00368075     EISSN: None     Source Type: Journal    
DOI: 10.1126/science.276.5320.1851     Document Type: Article

References (47)

1. R. A. Vescio, A. K. Lichtenstein, J. R. Berenson, in Cancer Treatment, C. M. Haskell, Ed. (Saunders, Philadelphia, 1995), pp. 1094-1116.
2. R. A. Kyle et al., Mayo Clin. Proc. 68, 26 (1993).
3. T. Hirano, Int. J. Cell Cloning 9, 166 (1991); T. Kishimoto, S. Akira, T. Taga, Science 258, 593 (1992); H. Uchiyama et al., Blood 82, 3712 (1993); A. Lichtenstein et al., ibid. 74, 1266 (1989); K. C. Anderson et al., ibid. 73, 1915 (1989); A. Lichtenstein, Y. Tu, C. Fady, R. Vescio, J. Berenson, Cell. Immunol. 162, 248 (1995).
4. T. Hirano, Int. J. Cell Cloning 9, 166 (1991); T. Kishimoto, S. Akira, T. Taga, Science 258, 593 (1992); H. Uchiyama et al., Blood 82, 3712 (1993); A. Lichtenstein et al., ibid. 74, 1266 (1989); K. C. Anderson et al., ibid. 73, 1915 (1989); A. Lichtenstein, Y. Tu, C. Fady, R. Vescio, J. Berenson, Cell. Immunol. 162, 248 (1995).
5. T. Hirano, Int. J. Cell Cloning 9, 166 (1991); T. Kishimoto, S. Akira, T. Taga, Science 258, 593 (1992); H. Uchiyama et al., Blood 82, 3712 (1993); A. Lichtenstein et al., ibid. 74, 1266 (1989); K. C. Anderson et al., ibid. 73, 1915 (1989); A. Lichtenstein, Y. Tu, C. Fady, R. Vescio, J. Berenson, Cell. Immunol. 162, 248 (1995).
6. T. Hirano, Int. J. Cell Cloning 9, 166 (1991); T. Kishimoto, S. Akira, T. Taga, Science 258, 593 (1992); H. Uchiyama et al., Blood 82, 3712 (1993); A. Lichtenstein et al., ibid. 74, 1266 (1989); K. C. Anderson et al., ibid. 73, 1915 (1989); A. Lichtenstein, Y. Tu, C. Fady, R. Vescio, J. Berenson, Cell. Immunol. 162, 248 (1995).
7. T. Hirano, Int. J. Cell Cloning 9, 166 (1991); T. Kishimoto, S. Akira, T. Taga, Science 258, 593 (1992); H. Uchiyama et al., Blood 82, 3712 (1993); A. Lichtenstein et al., ibid. 74, 1266 (1989); K. C. Anderson et al., ibid. 73, 1915 (1989); A. Lichtenstein, Y. Tu, C. Fady, R. Vescio, J. Berenson, Cell. Immunol. 162, 248 (1995).
8. T. Hirano, Int. J. Cell Cloning 9, 166 (1991); T. Kishimoto, S. Akira, T. Taga, Science 258, 593 (1992); H. Uchiyama et al., Blood 82, 3712 (1993); A. Lichtenstein et al., ibid. 74, 1266 (1989); K. C. Anderson et al., ibid. 73, 1915 (1989); A. Lichtenstein, Y. Tu, C. Fady, R. Vescio, J. Berenson, Cell. Immunol. 162, 248 (1995).
9. A. G. King, D. Wierda, K. S. Landreth, J. Immunol. 141, 2016 (1988); E. L. Kittler et al., Blood 79, 3168 (1992).
10. A. G. King, D. Wierda, K. S. Landreth, J. Immunol. 141, 2016 (1988); E. L. Kittler et al., Blood 79, 3168 (1992).
11. P. S. Moore et al., Virology 70, 549 (1996); C. Boshoff et al., Lancet 345, 1043 (1995); M. Schalling et al., Nature Med. 1, 707 (1995); C. Boshoff et al., ibid., p. 1274; W. Zhong, H. Wang, B. Herndier, D. Ganem, Proc. Natl. Acad. Sci. U.S.A. 93, 6641 (1996); G. Miller et al., N. Engl. J. Med. 334, 1292, (1996); D. H. Kedes et al., Nature Med. 2, 918 (1996); S.J. Gao et al., ibid., p. 925; V. Beral, Cancer Surv. 10, 5 (1991); T. A. Peterman, H. W. Jaffe, V. Beral, AIDS 7, 605 (1993); R. A. Weiss, Nature Med. 2, 277 (1996); J. Soulier et al., Blood 86, 1276 (1995); A. Gessain et al., ibid. 87, 414 (1996); M. Corbellino et al., Clin. Infect. Dis 22, 1120 (1996).
12. P. S. Moore et al., Virology 70, 549 (1996); C. Boshoff et al., Lancet 345, 1043 (1995); M. Schalling et al., Nature Med. 1, 707 (1995); C. Boshoff et al., ibid., p. 1274; W. Zhong, H. Wang, B. Herndier, D. Ganem, Proc. Natl. Acad. Sci. U.S.A. 93, 6641 (1996); G. Miller et al., N. Engl. J. Med. 334, 1292, (1996); D. H. Kedes et al., Nature Med. 2, 918 (1996); S.J. Gao et al., ibid., p. 925; V. Beral, Cancer Surv. 10, 5 (1991); T. A. Peterman, H. W. Jaffe, V. Beral, AIDS 7, 605 (1993); R. A. Weiss, Nature Med. 2, 277 (1996); J. Soulier et al., Blood 86, 1276 (1995); A. Gessain et al., ibid. 87, 414 (1996); M. Corbellino et al., Clin. Infect. Dis 22, 1120 (1996).
13. P. S. Moore et al., Virology 70, 549 (1996); C. Boshoff et al., Lancet 345, 1043 (1995); M. Schalling et al., Nature Med. 1, 707 (1995); C. Boshoff et al., ibid., p. 1274; W. Zhong, H. Wang, B. Herndier, D. Ganem, Proc. Natl. Acad. Sci. U.S.A. 93, 6641 (1996); G. Miller et al., N. Engl. J. Med. 334, 1292, (1996); D. H. Kedes et al., Nature Med. 2, 918 (1996); S.J. Gao et al., ibid., p. 925; V. Beral, Cancer Surv. 10, 5 (1991); T. A. Peterman, H. W. Jaffe, V. Beral, AIDS 7, 605 (1993); R. A. Weiss, Nature Med. 2, 277 (1996); J. Soulier et al., Blood 86, 1276 (1995); A. Gessain et al., ibid. 87, 414 (1996); M. Corbellino et al., Clin. Infect. Dis 22, 1120 (1996).
14. P. S. Moore et al., Virology 70, 549 (1996); C. Boshoff et al., Lancet 345, 1043 (1995); M. Schalling et al., Nature Med. 1, 707 (1995); C. Boshoff et al., ibid., p. 1274; W. Zhong, H. Wang, B. Herndier, D. Ganem, Proc. Natl. Acad. Sci. U.S.A. 93, 6641 (1996); G. Miller et al., N. Engl. J. Med. 334, 1292, (1996); D. H. Kedes et al., Nature Med. 2, 918 (1996); S.J. Gao et al., ibid., p. 925; V. Beral, Cancer Surv. 10, 5 (1991); T. A. Peterman, H. W. Jaffe, V. Beral, AIDS 7, 605 (1993); R. A. Weiss, Nature Med. 2, 277 (1996); J. Soulier et al., Blood 86, 1276 (1995); A. Gessain et al., ibid. 87, 414 (1996); M. Corbellino et al., Clin. Infect. Dis 22, 1120 (1996).
15. P. S. Moore et al., Virology 70, 549 (1996); C. Boshoff et al., Lancet 345, 1043 (1995); M. Schalling et al., Nature Med. 1, 707 (1995); C. Boshoff et al., ibid., p. 1274; W. Zhong, H. Wang, B. Herndier, D. Ganem, Proc. Natl. Acad. Sci. U.S.A. 93, 6641 (1996); G. Miller et al., N. Engl. J. Med. 334, 1292, (1996); D. H. Kedes et al., Nature Med. 2, 918 (1996); S.J. Gao et al., ibid., p. 925; V. Beral, Cancer Surv. 10, 5 (1991); T. A. Peterman, H. W. Jaffe, V. Beral, AIDS 7, 605 (1993); R. A. Weiss, Nature Med. 2, 277 (1996); J. Soulier et al., Blood 86, 1276 (1995); A. Gessain et al., ibid. 87, 414 (1996); M. Corbellino et al., Clin. Infect. Dis 22, 1120 (1996).
16. P. S. Moore et al., Virology 70, 549 (1996); C. Boshoff et al., Lancet 345, 1043 (1995); M. Schalling et al., Nature Med. 1, 707 (1995); C. Boshoff et al., ibid., p. 1274; W. Zhong, H. Wang, B. Herndier, D. Ganem, Proc. Natl. Acad. Sci. U.S.A. 93, 6641 (1996); G. Miller et al., N. Engl. J. Med. 334, 1292, (1996); D. H. Kedes et al., Nature Med. 2, 918 (1996); S.J. Gao et al., ibid., p. 925; V. Beral, Cancer Surv. 10, 5 (1991); T. A. Peterman, H. W. Jaffe, V. Beral, AIDS 7, 605 (1993); R. A. Weiss, Nature Med. 2, 277 (1996); J. Soulier et al., Blood 86, 1276 (1995); A. Gessain et al., ibid. 87, 414 (1996); M. Corbellino et al., Clin. Infect. Dis 22, 1120 (1996).
17. P. S. Moore et al., Virology 70, 549 (1996); C. Boshoff et al., Lancet 345, 1043 (1995); M. Schalling et al., Nature Med. 1, 707 (1995); C. Boshoff et al., ibid., p. 1274; W. Zhong, H. Wang, B. Herndier, D. Ganem, Proc. Natl. Acad. Sci. U.S.A. 93, 6641 (1996); G. Miller et al., N. Engl. J. Med. 334, 1292, (1996); D. H. Kedes et al., Nature Med. 2, 918 (1996); S.J. Gao et al., ibid., p. 925; V. Beral, Cancer Surv. 10, 5 (1991); T. A. Peterman, H. W. Jaffe, V. Beral, AIDS 7, 605 (1993); R. A. Weiss, Nature Med. 2, 277 (1996); J. Soulier et al., Blood 86, 1276 (1995); A. Gessain et al., ibid. 87, 414 (1996); M. Corbellino et al., Clin. Infect. Dis 22, 1120 (1996).
18. P. S. Moore et al., Virology 70, 549 (1996); C. Boshoff et al., Lancet 345, 1043 (1995); M. Schalling et al., Nature Med. 1, 707 (1995); C. Boshoff et al., ibid., p. 1274; W. Zhong, H. Wang, B. Herndier, D. Ganem, Proc. Natl. Acad. Sci. U.S.A. 93, 6641 (1996); G. Miller et al., N. Engl. J. Med. 334, 1292, (1996); D. H. Kedes et al., Nature Med. 2, 918 (1996); S.J. Gao et al., ibid., p. 925; V. Beral, Cancer Surv. 10, 5 (1991); T. A. Peterman, H. W. Jaffe, V. Beral, AIDS 7, 605 (1993); R. A. Weiss, Nature Med. 2, 277 (1996); J. Soulier et al., Blood 86, 1276 (1995); A. Gessain et al., ibid. 87, 414 (1996); M. Corbellino et al., Clin. Infect. Dis 22, 1120 (1996).
19. P. S. Moore et al., Virology 70, 549 (1996); C. Boshoff et al., Lancet 345, 1043 (1995); M. Schalling et al., Nature Med. 1, 707 (1995); C. Boshoff et al., ibid., p. 1274; W. Zhong, H. Wang, B. Herndier, D. Ganem, Proc. Natl. Acad. Sci. U.S.A. 93, 6641 (1996); G. Miller et al., N. Engl. J. Med. 334, 1292, (1996); D. H. Kedes et al., Nature Med. 2, 918 (1996); S.J. Gao et al., ibid., p. 925; V. Beral, Cancer Surv. 10, 5 (1991); T. A. Peterman, H. W. Jaffe, V. Beral, AIDS 7, 605 (1993); R. A. Weiss, Nature Med. 2, 277 (1996); J. Soulier et al., Blood 86, 1276 (1995); A. Gessain et al., ibid. 87, 414 (1996); M. Corbellino et al., Clin. Infect. Dis 22, 1120 (1996).
20. P. S. Moore et al., Virology 70, 549 (1996); C. Boshoff et al., Lancet 345, 1043 (1995); M. Schalling et al., Nature Med. 1, 707 (1995); C. Boshoff et al., ibid., p. 1274; W. Zhong, H. Wang, B. Herndier, D. Ganem, Proc. Natl. Acad. Sci. U.S.A. 93, 6641 (1996); G. Miller et al., N. Engl. J. Med. 334, 1292, (1996); D. H. Kedes et al., Nature Med. 2, 918 (1996); S.J. Gao et al., ibid., p. 925; V. Beral, Cancer Surv. 10, 5 (1991); T. A. Peterman, H. W. Jaffe, V. Beral, AIDS 7, 605 (1993); R. A. Weiss, Nature Med. 2, 277 (1996); J. Soulier et al., Blood 86, 1276 (1995); A. Gessain et al., ibid. 87, 414 (1996); M. Corbellino et al., Clin. Infect. Dis 22, 1120 (1996).
21. P. S. Moore et al., Virology 70, 549 (1996); C. Boshoff et al., Lancet 345, 1043 (1995); M. Schalling et al., Nature Med. 1, 707 (1995); C. Boshoff et al., ibid., p. 1274; W. Zhong, H. Wang, B. Herndier, D. Ganem, Proc. Natl. Acad. Sci. U.S.A. 93, 6641 (1996); G. Miller et al., N. Engl. J. Med. 334, 1292, (1996); D. H. Kedes et al., Nature Med. 2, 918 (1996); S.J. Gao et al., ibid., p. 925; V. Beral, Cancer Surv. 10, 5 (1991); T. A. Peterman, H. W. Jaffe, V. Beral, AIDS 7, 605 (1993); R. A. Weiss, Nature Med. 2, 277 (1996); J. Soulier et al., Blood 86, 1276 (1995); A. Gessain et al., ibid. 87, 414 (1996); M. Corbellino et al., Clin. Infect. Dis 22, 1120 (1996).
22. P. S. Moore et al., Virology 70, 549 (1996); C. Boshoff et al., Lancet 345, 1043 (1995); M. Schalling et al., Nature Med. 1, 707 (1995); C. Boshoff et al., ibid., p. 1274; W. Zhong, H. Wang, B. Herndier, D. Ganem, Proc. Natl. Acad. Sci. U.S.A. 93, 6641 (1996); G. Miller et al., N. Engl. J. Med. 334, 1292, (1996); D. H. Kedes et al., Nature Med. 2, 918 (1996); S.J. Gao et al., ibid., p. 925; V. Beral, Cancer Surv. 10, 5 (1991); T. A. Peterman, H. W. Jaffe, V. Beral, AIDS 7, 605 (1993); R. A. Weiss, Nature Med. 2, 277 (1996); J. Soulier et al., Blood 86, 1276 (1995); A. Gessain et al., ibid. 87, 414 (1996); M. Corbellino et al., Clin. Infect. Dis 22, 1120 (1996).
23. P. S. Moore et al., Virology 70, 549 (1996); C. Boshoff et al., Lancet 345, 1043 (1995); M. Schalling et al., Nature Med. 1, 707 (1995); C. Boshoff et al., ibid., p. 1274; W. Zhong, H. Wang, B. Herndier, D. Ganem, Proc. Natl. Acad. Sci. U.S.A. 93, 6641 (1996); G. Miller et al., N. Engl. J. Med. 334, 1292, (1996); D. H. Kedes et al., Nature Med. 2, 918 (1996); S.J. Gao et al., ibid., p. 925; V. Beral, Cancer Surv. 10, 5 (1991); T. A. Peterman, H. W. Jaffe, V. Beral, AIDS 7, 605 (1993); R. A. Weiss, Nature Med. 2, 277 (1996); J. Soulier et al., Blood 86, 1276 (1995); A. Gessain et al., ibid. 87, 414 (1996); M. Corbellino et al., Clin. Infect. Dis 22, 1120 (1996).
24. P. S. Moore et al., Virology 70, 549 (1996); C. Boshoff et al., Lancet 345, 1043 (1995); M. Schalling et al., Nature Med. 1, 707 (1995); C. Boshoff et al., ibid., p. 1274; W. Zhong, H. Wang, B. Herndier, D. Ganem, Proc. Natl. Acad. Sci. U.S.A. 93, 6641 (1996); G. Miller et al., N. Engl. J. Med. 334, 1292, (1996); D. H. Kedes et al., Nature Med. 2, 918 (1996); S.J. Gao et al., ibid., p. 925; V. Beral, Cancer Surv. 10, 5 (1991); T. A. Peterman, H. W. Jaffe, V. Beral, AIDS 7, 605 (1993); R. A. Weiss, Nature Med. 2, 277 (1996); J. Soulier et al., Blood 86, 1276 (1995); A. Gessain et al., ibid. 87, 414 (1996); M. Corbellino et al., Clin. Infect. Dis 22, 1120 (1996).
25. E. Cesarman, Y. Chang, P. S. Moore, J. W. Said, D. M. Knowles, N. Engl. J. Med. 332, 1186 (1995).
26. 233 sequence represents a 233-bp fragment of the KS330 Bam region of KSHV. The KS330 Bam region was a sequence that was originally isolated from KS genomic DNA by representational difference analysis.
27. S.-J. Gao et al., N. Engl. J. Med. 335, 233 (1996).
28. C. Pastore et al., Br. J. Haematol. 91, 918 (1995).
29. P. S. Moore, C. Boshoff, R. A. Weiss, Y. Chang, Science 274, 1739 (1996).
30. 2 incubator. The growth medium was changed every week. Once a confluent, adherent cell monolayer developed, the monolayer was washed three times with phosphate-buffered saline (PBS). The adherent bone marrow stromal cells were harvested with 0.5% trypsin in Hanks' buffered saline solution (Irvine Scientific), washed with PBS, and collected by centrifugation.
31. 233 primers. The PCR amplification was repeated up to three times to assure the reproducibility of the results. Samples were also evaluated in a blinded fashion (the source of bone marrow stromal cells was unknown by the technician).
32. 233 sequence was used for hybridization as described (7).
33. 233 PCR product was cloned into the pCR 2.1 vector (Invitrogen, San Diego, CA) and sequenced with the Sequenase Version 2.0 Sequencing Kit (Amersham Life Science, Cleveland, OH) according to the manufacturers' instructions.
34. M. B. Rettig et al., data not shown.
35. Serial paraffin sections were mounted on glass slides, deparaffinized, and immersed in 3% hydrogen peroxide to quench endogenous peroxidase activity. After proteinase digestion for 30 min at 37°C, slides were incubated sequentially with 10% paraformaldehyde solution for 5 min at room temperature and with glycine solution at 37°C for 5 min. The slides were then dehydrated and air-dried, and a cover slip was applied and then heated at 95°C for 4 min to denature viral DNA. Sections were incubated for 18 hours at 37°C with a biotinylated probe diluted 1:100 to 1:300 in 50% formamide, 2× standard saline citrate (SSC), Denhardt's solution, dextrose sulfate, and salmon sperm DNA. The probe was in sense orientation with the following sequence: 5′-TGC-AGCAGCTGTTGGTGTACCACATCTACT-3′; T denotes biotinylated thymidine. The sequence of this probe was identical to that of the probe used for Southern blotting, except for the addition of 5 bp to the 3′ end (7). Slides were then washed in tris-buffered saline and 0.02% SDS and incubated with a monoclonal mouse antibody to biotin (Dako, Carpinteria, CA) followed by horseradish peroxidase-conjugated rabbit antibody to mouse and goat antibody to rabbit immunoglobulins (Dako). The reaction product was visualized by means of the diaminobenzidene reaction. To determine if in situ hybridization signals were from specific hybridization to DNA and RNA, we pretreated slides with RNase (1 mg/ml) (DNase-free, Sigma, St. Louis, MO) and DNase (1 mg/ml) (RNase-free, Boehringer Mannheim, Indianapolis, IN).
36. After trypsinization, bone marrow stromal cells were pelleted and fixed with formalin. Pellets were embedded in paraffin and then sectioned. Staining for CD31, CD34, CD68, CD1a, CD83, vimentin, and lysozyme was performed on deparaffinized sections with monoclonal antibodies (all antibodies were from Dako, Carpinteria, CA, except antibody to CD83, which was from Immunotech, Marseille, France) by using immunoperoxidase methods as described [J. Ho et al., Appl. Immunohistochem. 2, 282 (1994)]. Staining for fascin was performed as described [G. S. Pinkus et al., Am. J. Pathol. 150, 543 (1997)].
37. After trypsinization, bone marrow stromal cells were pelleted and fixed with formalin. Pellets were embedded in paraffin and then sectioned. Staining for CD31, CD34, CD68, CD1a, CD83, vimentin, and lysozyme was performed on deparaffinized sections with monoclonal antibodies (all antibodies were from Dako, Carpinteria, CA, except antibody to CD83, which was from Immunotech, Marseille, France) by using immunoperoxidase methods as described [J. Ho et al., Appl. Immunohistochem. 2, 282 (1994)]. Staining for fascin was performed as described [G. S. Pinkus et al., Am. J. Pathol. 150, 543 (1997)].
38. G. Moseiglos et al., Am. J. Pathol. 148, 593 (1996); L.-J. Zhou and T. F. Tedder, J. Immunol. 154, 3821 (1995).
39. G. Moseiglos et al., Am. J. Pathol. 148, 593 (1996); L.-J. Zhou and T. F. Tedder, J. Immunol. 154, 3821 (1995).
40. Cells were fixed in glutaraldehyde, pelleted, and embedded for electron microscopy as described [J. W. Said et al., Stood 87, 4937 (1996)]. Ultrathin sections were stained with uranyl acetate and lead citrate and examined in a transmission electron microscope (JEOL, Peabody, MA).
41. Total RNA was prepared with RNAzol (TelTest, Friendswood, TX) according to the manufacturer's instructions. First-strand synthesis was performed at 42°C for 1 hour wifh 5 μg of total RNA. PCR was done in 200 μM for each deoxynucleotide triphosphate and 5 pmol of each vIL-6 primer (7). The PCR sequence was as follows: 44 cycles at 58°C for 1 min, 72°C for 1.5 min, 94°C for 1 min with a 5-min initial denaturation at 95°C, and a final 5-min elongation step. PCR product (10 μu) was electrophoresed on a 1% agarose gel impregnated with ethidium bramide and then photographed. The expected PCR product is 695 bp. RT-PCR with β-actin primers (12) was performed on samples (3 μg of total RNA) that were RT-PCR negative with the vIL-6 primers.
42. R. A. Kyle, Am. J. Med. 64, 814 (1978); J. Blade et al., Br. J. Haematol. 81, 391 (1992); F. D. Lindström and U. Dahlström, Clin. Immunol. Immunopathol. 10, 168 (1978); G. Paladini et al., Recenti Prog. Med. 80, 123 (1989).
43. R. A. Kyle, Am. J. Med. 64, 814 (1978); J. Blade et al., Br. J. Haematol. 81, 391 (1992); F. D. Lindström and U. Dahlström, Clin. Immunol. Immunopathol. 10, 168 (1978); G. Paladini et al., Recenti Prog. Med. 80, 123 (1989).
44. R. A. Kyle, Am. J. Med. 64, 814 (1978); J. Blade et al., Br. J. Haematol. 81, 391 (1992); F. D. Lindström and U. Dahlström, Clin. Immunol. Immunopathol. 10, 168 (1978); G. Paladini et al., Recenti Prog. Med. 80, 123 (1989).
45. R. A. Kyle, Am. J. Med. 64, 814 (1978); J. Blade et al., Br. J. Haematol. 81, 391 (1992); F. D. Lindström and U. Dahlström, Clin. Immunol. Immunopathol. 10, 168 (1978); G. Paladini et al., Recenti Prog. Med. 80, 123 (1989).
46. B. Dubois et al., J. Exp. Med. 185, 941 (1997).
47. We thank A. Lichtenstein for critical comments, G. S. Pinkus and J. L. Pinkus for assistance with fascin staining, and T. Moss (BIS Laboratories, Reseda, CA) for providing relevant samples. Supported by funds from the Veterans Administration.